EUVIMEDEUVIMED entdecken
Open Access

Ototoxicity associated with high‐dose carboplatin for patients with previously treated germ cell tumors

Samuel A Funt iD, Andrea Knezevic iD, Kaamilah Wilson, Maria Bromberg iD, Amy Budnick, Kerri L O'Connor, Deaglan J McHugh iD, Erik Larsen iD, Dean F Bajorin, Robert J Motzer iD, Emily S Tonorezos iD, Sujata Patil und 1 weitere

Cancer · 2023

DOI: 10.1002/cncr.34991 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Samuel A Funt und 12 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Ototoxicity, Neoplasms, Germ Cell and Embryonal, Hearing Loss. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High‐dose carboplatin is an essential part of curative high‐dose chemotherapy (HDCT) for patients with previously treated germ cell tumors (GCTs). Although hearing loss (HL) is a known side effect of HDCT, data on its severity and characteristics are limited.

Methods

Eligible patients received HDCT for GCTs from 1993 to 2017 and had audiograms before and after HDCT. HL severity was classified by American Speech‐Language‐Hearing Association criteria, and mean change in hearing threshold at each frequency (0.25–8 kHz) was estimated from pre‐ to post‐HDCT and between HDCT cycles.

Results

Of 115 patients (median age, 32 years), 102 (89%) received three cycles of HDCT. Of 106 patients with normal hearing to mild HL in the speech frequencies (0.5–4 kHz) before HDCT, 70 (66%) developed moderate to profound HL in the speech frequencies after HDCT. Twenty‐five patients (22%) were recommended for hearing aids after HDCT. Patients with moderate to profound HL isolated to the higher frequencies (6–8 kHz) before HDCT were more likely to develop moderate to profound HL in the speech frequencies after HDCT (94% vs. 61%; p = .01) and to be recommended for hearing aids (39% vs. 18%; p = .05).

Conclusions

HL was frequent after HDCT for GCTs, with most patients developing at least moderate HL in the speech frequencies and approximately one in five recommended for hearing aids. Moderate to profound HL isolated to high frequencies at baseline was predictive of more clinically significant hearing impairment after HDCT. Plain Language Summary Some patients with germ cell tumors, the most common malignancy in adolescent and young adult men, are not cured with standard‐dose chemotherapy and require high‐dose chemotherapy (HDCT). Using detailed hearing assessments of patients receiving HDCT, we found that most patients developed significant hearing loss and that one in five needed hearing aids. Thus, strategies to reduce this side effect are urgently needed, and all patients receiving HDCT should have a hearing test after therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OtotoxicityNeoplasms, Germ Cell and EmbryonalHearing LossMaleAdolescentYoung AdultHumansAdultCarboplatinAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

cancer treatmentgerm cell tumorhearing losshigh-dose carboplatinototoxicitysurvivorship

Substanzen

Carboplatin

Autor:innen und Institutionen

  • Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Weill Cornell Medical College, New York, New York, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Formerly of Decibel Therapeutics, Boston, Massachusetts, USA.
  • National Cancer Institute, Rockville, Maryland, USA.

ORCID-Profile: Samuel A Funt, Andrea Knezevic, Maria Bromberg, Deaglan J McHugh, Erik Larsen, Robert J Motzer, Emily S Tonorezos, Darren R Feldman

Förderung

  • NCI NIH HHS

Zitieren

APA

Funt, S. A., Knezevic, A., Wilson, K., Bromberg, M., Budnick, A., O'Connor, K. L., McHugh, D. J., Larsen, E., Bajorin, D. F., Motzer, R. J., Tonorezos, E. S., Patil, S., & Feldman, D. R. (2023). Ototoxicity associated with high‐dose carboplatin for patients with previously treated germ cell tumors. Cancer. https://doi.org/10.1002/cncr.34991

Vancouver

Funt SA, Knezevic A, Wilson K, Bromberg M, Budnick A, O'Connor KL, et al. Ototoxicity associated with high‐dose carboplatin for patients with previously treated germ cell tumors. Cancer. 2023. doi:10.1002/cncr.34991

BibTeX
@article{Funt2023,
  author = {Funt, Samuel A and Knezevic, Andrea and Wilson, Kaamilah and Bromberg, Maria and Budnick, Amy and O'Connor, Kerri L and McHugh, Deaglan J and Larsen, Erik and Bajorin, Dean F and Motzer, Robert J and Tonorezos, Emily S and Patil, Sujata and Feldman, Darren R},
  title = {Ototoxicity associated with high‐dose carboplatin for patients with previously treated germ cell tumors},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34991}
}
Kostenlos starten →